Antibody-based therapy of non-Hodgkin's lymphoma

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Monoclonal antibodies (mAb) have dramatically advanced our ability to treat non-Hodgkin's lymphoma (NHL), and there has been a virtual explosion of clinical data regarding their use. Rituximab is a humanized anti-CD20 mAb and has significant single agent activity in follicular lymphoma, and to a lesser extent in mantle-cell and diffuse large B-cell lymphoma (DLCL). Rituximab appears to have synergistic activity with cytotoxic chemotherapy and the combination has recently demonstrated improved rates of complete remission (CR) and overall survival in older patients with DLCL. Alemtuzumab (Campath-IH) is a humanized mAb targeting CD52 and has recently been approved in the USA for the treatment of fludarabine-refractory B-cell chronic lymphocytic leukaemia. Impressive activity has also been demonstrated in T-cell prolymphocytic leukaemia and mycosis fungoides. The radioconjugated anti-CD20 mAbs ibritumomab tiuxetan and I 131-tositumomab also have impressive clinical activity in low-grade B-cell NHL, and the former has demonstrated superior CR rates to rituximab. Myelosuppression is more significant however, and their place in the treatment algorithm remains to be clearly defined. Other immunotoxins (e.g. BL22) and mAb against alternate targets (e.g. epratuzumab, humanized anti-CD22) are in development.

Original languageEnglish (US)
Pages (from-to)449-465
Number of pages17
JournalBest Practice and Research: Clinical Haematology
Volume15
Issue number3
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Non-Hodgkin's Lymphoma
Lymphoma, Large B-Cell, Diffuse
Monoclonal Antibodies
Cells
Antibodies
T-Cell Prolymphocytic Leukemia
Antibodies, Monoclonal, Humanized
Immunotoxins
Mycosis Fungoides
Follicular Lymphoma
Chemotherapy
T-cells
Explosions
B-Cell Lymphoma
B-Cell Chronic Lymphocytic Leukemia
Combination Drug Therapy
Refractory materials
Therapeutics
Survival
Rituximab

Keywords

  • Alemtuzumab
  • Antibody-dependent cellular cytotoxicity
  • Chimeric
  • Complement-dependent cytotoxicity
  • Complementarity-determining region
  • I -tositumomab
  • Ibritumomab tiuxetan
  • Monoclonal antibody
  • Radioimmunotherapy
  • Rituximab

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Antibody-based therapy of non-Hodgkin's lymphoma. / Foran, James M.

In: Best Practice and Research: Clinical Haematology, Vol. 15, No. 3, 2002, p. 449-465.

Research output: Contribution to journalArticle

@article{527d64f7b7844673a5d10192305be302,
title = "Antibody-based therapy of non-Hodgkin's lymphoma",
abstract = "Monoclonal antibodies (mAb) have dramatically advanced our ability to treat non-Hodgkin's lymphoma (NHL), and there has been a virtual explosion of clinical data regarding their use. Rituximab is a humanized anti-CD20 mAb and has significant single agent activity in follicular lymphoma, and to a lesser extent in mantle-cell and diffuse large B-cell lymphoma (DLCL). Rituximab appears to have synergistic activity with cytotoxic chemotherapy and the combination has recently demonstrated improved rates of complete remission (CR) and overall survival in older patients with DLCL. Alemtuzumab (Campath-IH) is a humanized mAb targeting CD52 and has recently been approved in the USA for the treatment of fludarabine-refractory B-cell chronic lymphocytic leukaemia. Impressive activity has also been demonstrated in T-cell prolymphocytic leukaemia and mycosis fungoides. The radioconjugated anti-CD20 mAbs ibritumomab tiuxetan and I 131-tositumomab also have impressive clinical activity in low-grade B-cell NHL, and the former has demonstrated superior CR rates to rituximab. Myelosuppression is more significant however, and their place in the treatment algorithm remains to be clearly defined. Other immunotoxins (e.g. BL22) and mAb against alternate targets (e.g. epratuzumab, humanized anti-CD22) are in development.",
keywords = "Alemtuzumab, Antibody-dependent cellular cytotoxicity, Chimeric, Complement-dependent cytotoxicity, Complementarity-determining region, I -tositumomab, Ibritumomab tiuxetan, Monoclonal antibody, Radioimmunotherapy, Rituximab",
author = "Foran, {James M}",
year = "2002",
doi = "10.1053/beha.2002.0222",
language = "English (US)",
volume = "15",
pages = "449--465",
journal = "Best Practice and Research in Clinical Haematology",
issn = "1521-6926",
publisher = "Bailliere Tindall Ltd",
number = "3",

}

TY - JOUR

T1 - Antibody-based therapy of non-Hodgkin's lymphoma

AU - Foran, James M

PY - 2002

Y1 - 2002

N2 - Monoclonal antibodies (mAb) have dramatically advanced our ability to treat non-Hodgkin's lymphoma (NHL), and there has been a virtual explosion of clinical data regarding their use. Rituximab is a humanized anti-CD20 mAb and has significant single agent activity in follicular lymphoma, and to a lesser extent in mantle-cell and diffuse large B-cell lymphoma (DLCL). Rituximab appears to have synergistic activity with cytotoxic chemotherapy and the combination has recently demonstrated improved rates of complete remission (CR) and overall survival in older patients with DLCL. Alemtuzumab (Campath-IH) is a humanized mAb targeting CD52 and has recently been approved in the USA for the treatment of fludarabine-refractory B-cell chronic lymphocytic leukaemia. Impressive activity has also been demonstrated in T-cell prolymphocytic leukaemia and mycosis fungoides. The radioconjugated anti-CD20 mAbs ibritumomab tiuxetan and I 131-tositumomab also have impressive clinical activity in low-grade B-cell NHL, and the former has demonstrated superior CR rates to rituximab. Myelosuppression is more significant however, and their place in the treatment algorithm remains to be clearly defined. Other immunotoxins (e.g. BL22) and mAb against alternate targets (e.g. epratuzumab, humanized anti-CD22) are in development.

AB - Monoclonal antibodies (mAb) have dramatically advanced our ability to treat non-Hodgkin's lymphoma (NHL), and there has been a virtual explosion of clinical data regarding their use. Rituximab is a humanized anti-CD20 mAb and has significant single agent activity in follicular lymphoma, and to a lesser extent in mantle-cell and diffuse large B-cell lymphoma (DLCL). Rituximab appears to have synergistic activity with cytotoxic chemotherapy and the combination has recently demonstrated improved rates of complete remission (CR) and overall survival in older patients with DLCL. Alemtuzumab (Campath-IH) is a humanized mAb targeting CD52 and has recently been approved in the USA for the treatment of fludarabine-refractory B-cell chronic lymphocytic leukaemia. Impressive activity has also been demonstrated in T-cell prolymphocytic leukaemia and mycosis fungoides. The radioconjugated anti-CD20 mAbs ibritumomab tiuxetan and I 131-tositumomab also have impressive clinical activity in low-grade B-cell NHL, and the former has demonstrated superior CR rates to rituximab. Myelosuppression is more significant however, and their place in the treatment algorithm remains to be clearly defined. Other immunotoxins (e.g. BL22) and mAb against alternate targets (e.g. epratuzumab, humanized anti-CD22) are in development.

KW - Alemtuzumab

KW - Antibody-dependent cellular cytotoxicity

KW - Chimeric

KW - Complement-dependent cytotoxicity

KW - Complementarity-determining region

KW - I -tositumomab

KW - Ibritumomab tiuxetan

KW - Monoclonal antibody

KW - Radioimmunotherapy

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=0036459266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036459266&partnerID=8YFLogxK

U2 - 10.1053/beha.2002.0222

DO - 10.1053/beha.2002.0222

M3 - Article

VL - 15

SP - 449

EP - 465

JO - Best Practice and Research in Clinical Haematology

JF - Best Practice and Research in Clinical Haematology

SN - 1521-6926

IS - 3

ER -